cyproheptadine has been researched along with cyclin d1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beheshti Zavareh, R; Chow, S; Datti, A; Gronda, M; Hedley, DW; Hurren, R; Jamal, N; Lee, K; Liang, SB; Mao, X; Messner, H; Schimmer, AD; Shi, CX; Stewart, AK; Tiedemann, R; Trudel, S; Wang, X; Wrana, JL; Xu, GW; Zhu, Y | 1 |
| Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE | 1 |
2 other study(ies) available for cyproheptadine and cyclin d1
| Article | Year |
|---|---|
Cyproheptadine displays preclinical activity in myeloma and leukemia.
Topics: Animals; Apoptosis; Cell Line; Cell Line, Tumor; Cyclin D1; Cyclin D2; Cyclin D3; Cyclins; Cyproheptadine; Drug Screening Assays, Antitumor; Gene Expression Regulation; Humans; Leukemia, Myeloid, Acute; Mice; Multiple Myeloma | 2008 |
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
Topics: Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cyclin D1; Cyproheptadine; Disease Models, Animal; Histamine H1 Antagonists; Histone Deacetylase Inhibitors; Lymphoma, Mantle-Cell; Mice; Protease Inhibitors; Pyrazines | 2009 |